Interested in developing degrader drugs that could save lives of kids with cancer? Look no further. We are recruiting 4 scientists at @UoDCeTPD to do just that as part of our @CancerGrand#CancerGrandChallenges KOODAC team. Role 1/4: Senior Lead Scientist https://t.co/jIDigaUcr7
Nurix scientist Chad Hewitt, Ph.D., will discuss the use of Nurix’s DeLigase platform to drug pediatric cancer targets in its work as a member of both @CancerGrand’s #TeamKOODAC and @cac2org.
Learn more about the #DrugDiscoveryChemistry conference: https://t.co/ZVuQtNxw3C
A new paper from our lab that is the first to report inhibition data against the alpha and gamma carbonic anhydrases from Enterococcus faecium is out today. Great job by @Weiwei_An_ and @Katrina_Holly98 for leading the way.
https://t.co/z5a6sgVktg
Welcome to the official Nurix Therapeutics Twitter account! Follow along as we blaze a new path in medicine. Visit our website to learn more: https://t.co/SHmryDX2EI $NRIX
Our article on optimization of a fluoromethylketone UCHL1 inhibitor and it's use as a probe for UCHL1 in cancer was published online today in the @Molecules_MDPI @PUCancerCenter @WendtLab_cancer@Purdue_MCMP
https://t.co/F8pwDoij0w